Annuncio pubblicitario
Italia markets closed

  • FTSE MIB

    33.922,16
    +40,66 (+0,12%)
     

  • Dow Jones

    37.933,72
    +158,34 (+0,42%)
     

  • Nasdaq

    15.252,68
    -348,82 (-2,24%)
     

  • Nikkei 225

    37.068,35
    -1.011,35 (-2,66%)
     

  • Petrolio

    83,21
    +0,48 (+0,58%)
     

  • Bitcoin EUR

    60.323,20
    +910,09 (+1,53%)
     

  • CMC Crypto 200

    1.383,97
    +71,35 (+5,44%)
     

  • Oro

    2.408,80
    +10,80 (+0,45%)
     

  • EUR/USD

    1,0655
    +0,0009 (+0,09%)
     

  • S&P 500

    4.959,74
    -51,38 (-1,03%)
     

  • HANG SENG

    16.224,14
    -161,73 (-0,99%)
     

  • Euro Stoxx 50

    4.918,09
    -18,48 (-0,37%)
     

  • EUR/GBP

    0,8610
    +0,0055 (+0,64%)
     

  • EUR/CHF

    0,9697
    -0,0013 (-0,14%)
     

  • EUR/CAD

    1,4648
    -0,0003 (-0,02%)
     

Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event

Aeterna Zentaris Inc
·2 minuto per la lettura
Aeterna Zentaris Inc
Aeterna Zentaris Inc

Live video webcast on Thursday, January 19th at 3:00 PM ET

TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 19, 2023 at 3:00 PM ET.

A live video webcast of the presentation will be available on the Events page of the Company’s website (www.zentaris.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

ANNUNCIO PUBBLICITARIO

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen™; Ghryvelin®), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need, in collaboration with Novo Nordisk.

Aeterna Zentaris is dedicated to the development of therapeutic assets and has recently taken steps to establish a growing pre-clinical pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease). Additionally, the Company is developing an oral prophylactic bacterial vaccine against SARS-CoV-2 (COVID-19) and Chlamydia trachomatis.

For more information, please visit www.zentaris.com and connect with the Company on Twitter, LinkedIn and Facebook.

Investor Contact:

Jenene Thomas
JTC Team
T (US): +1 (833) 475-8247
E: aezs@jtcir.com